R&D Trends

Fluxion Biosciences, Stanford collaborate on circulating tumor cell analysis

Friday, June 29, 2012 11:45 AM

Fluxion Biosciences, a San Francisco-based provider of cellular analysis tools for use in critical life science, has formed a collaboration with the Stanford University School of Medicine to develop tests to help deliver more effective therapies to cancer patients.

More... »

Soligenix, IDRI to develop thermostabilized biodefense vaccines

Wednesday, June 27, 2012 09:44 AM

Soligenix, a development stage biopharmaceutical company, has entered into a collaboration with the Infectious Disease Research Institute (IDRI) of Seattle, Wash., to develop select biodefense vaccines using IDRI's potent and safe synthetic adjuvants in conjunction with Soligenix's proprietary subunit proteins and thermostability platform, ThermoVax. 

More... »

Catalent, Bend Research to provide integrated solutions for oral controlled-release technologies

Monday, June 25, 2012 10:17 AM

Catalent Pharma Solutions of Somerset, N.J., and Bend Research of Bend, Ore., have entered into an agreement to provide integrated solutions for pharmaceutical companies seeking to develop and manufacture specialized multiparticulate oral controlled-release products.

More... »

MJFF launches $14M Edmond J. Safra Core programs for Parkinson’s research

Friday, June 22, 2012 01:00 PM

The Michael J. Fox Foundation for Parkinson's Research (MJFF) has officially opened its Therapeutic Pipeline Program, a newly created funding mechanism that invites research proposals from industry and academic investigators to drive pre-clinical and clinical Parkinson's disease (PD) drug development.

More... »

Survey: Pharma execs focus on regulation and organic growth

Friday, June 22, 2012 12:09 PM

Pharmaceutical executives say they will focus as much time and energy ahead in navigating the regulatory environment as they will on organic growth, according to a recent survey by KPMG, the U.S. audit, tax and advisory firm.

More... »

AstraZeneca, Karolinska Institutet collaborate on molecular imaging research

Thursday, June 21, 2012 04:29 PM

Global biopharmaceutical company AstraZeneca and Karolinska Institutet, a medical university in Sweden, have entered into a three year collaborative research agreement that will apply state-of-the-art molecular imaging technologies to generate novel diagnostic imaging tools and further the development of AstraZeneca’s neuroscience R&D pipeline.

More... »

BIO-clusters Lyonbiopole, Alsace BioValley, CQDM to foster R&D

Thursday, June 21, 2012 12:10 PM

Lyonbiopole, a French competitiveness cluster of 110 members focused on infectious diseases and cancers, has joined the existing consortium between Alsace BioValley, a French competitiveness cluster dedicated to life sciences and health, and Quebec Consortium for Drug Discovery (CQDM).

More... »

IPC leads effort to clarify the genetic architecture of psoriasis

Wednesday, June 20, 2012 03:47 PM

The International Psoriasis Council (IPC) announced the publication of a report in the British Journal of Dermatology’s June edition that summarizes the IPC’s efforts to establish collaboration among leading geneticists and dermatologists to advance the understanding of the genetic basis of psoriasis.

More... »

Seven global biopharmas form neuroscience consortium

Wednesday, June 20, 2012 02:56 PM

Seven global biopharmaceutical companies have formed the Massachusetts Neuroscience Consortium, which will fund pre-clinical neuroscience at Massachusetts academic and research institutions. Participants include Abbott, Biogen Idec, EMD Serono, Janssen Research & Development, Merck, Pfizer and Sunovion Pharmaceuticals.

More... »

Standardized trial endpoints to help health authorities tackle respiratory diseases

Wednesday, June 20, 2012 12:16 PM

Science is standardizing the way respiratory health is measured, helping to judge the effectiveness of drug treatments better than ever, according to a new report by healthcare experts GBI Research.

More... »